The evaluation of serum biomarkers in patients with sarcoidosis: Can visfatin be a new biomarker for sarcoidosis? Source: International Congress 2017 – Rare diseases Year: 2017
Elevated circulating concentrations of adiponectin in sarcoidosis – a new marker of disease? Source: Annual Congress 2006 - Clinical features and disease markers of sarcoidosis Year: 2006
Serum markers of acute sarcoidosis. Source: Virtual Congress 2020 – Genetics and biomarkers for diagnosis and prognosis of granulomatous lung diseases Year: 2020
Serum leptin, insulin and C-reactive protein (CRP) in patients with pulmonary tuberculosis Source: Eur Respir J 2006; 28: Suppl. 50, 343s Year: 2006
Usefulness of serum procalcitonin in lung cancer patients with elevated serum C-reactive protein level Source: Annual Congress 2011 - Instructive clinical aspects of lung cancer Year: 2011
Levels of serum amyloid A (SAA) and C-reactive protein (CRP) in stable COPD patients and its relationship with disease severity. Source: International Congress 2017 – COPD biomarkers Year: 2017
The relation of serum interleukin-6 and C-reactive protein to clinical parameters in pulmonary tuberculosis Source: Eur Respir J 2004; 24: Suppl. 48, 35s Year: 2004
Is there a relationship between severity of COPD and C-reactive protein (CRP) levels? Source: Eur Respir J 2006; 28: Suppl. 50, 37s Year: 2006
Prognosis value of initial C-reactive protein (CRP) assay in patients with community acquired pneumonia Source: Annual Congress 2008 - Community-acquired pneumonia: prognosis, complications and prevention Year: 2008
The relationship between level of C-reactive protein in blood serum and clinical manifestations of the disease in patients with pulmonary tuberculosis Source: Annual Congress 2010 - Tuberculosis: metabolic insights Year: 2010
Serum concentration of C-reactive protein is not a good marker of bronchial hyperreactivity Source: Annual Congress 2007 - New mechanisms in the pathogenesis of asthma and allergy Year: 2007
Usefulness of inflammatory markers: procalcitonin, neopterin, C-reactive protein and MR-proANP in the follow-up of patients with chronic obstructive pulmonary disease Source: Annual Congress 2008 - Biomarkers and antibiotic treatment of exacerbations of COPD Year: 2008
C-reactive protein (CRP) at admission: is it really usefull in COVID-19 pneumonia? Source: Virtual Congress 2021 – COVID - 19 biomarkers Year: 2021
D-dimer to C-reactive protein (CRP) ratio in patients with suspected pulmonary embolism Source: Annual Congress 2010 - Pulmonary embolism Year: 2010
High serum procalcitonin and C-reactive protein levels can exclude tuberculosis in community-acquired pneumonia patients with atypical presentation Source: Annual Congress 2010 - Aetiology of lower respiratory tract infections and treatment in special situations Year: 2010
Levels of YKL-40 in serum and sputum of patients diagnosed with hypersensitivity pneumonitis: A pilot study. Source: International Congress 2018 – CTD-ILD and hypersensitivity pneumonitis: mechanistic insights and prognostic markers Year: 2018
Serum neopterin and IL-6 as biomarkers in patients with COPD. Source: International Congress 2017 – Novel molecular and genetic targets in COPD Year: 2017
Procalcitonin and C-reactive protein levels correlate worse with organ failure than NT-proBNP levels in septic patients Source: Eur Respir J 2006; 28: Suppl. 50, 61s Year: 2006
The investigation of diagnostic value of serum reactive protein (CRP) in patients with pleural effusion Source: Eur Respir J 2006; 28: Suppl. 50, 374s Year: 2006
Individual variation in the levels of procalcitonin, neopterin, CRP and MR-proANP during a COPD exacerbation and clinical stable state Source: Annual Congress 2009 - Exacerbations of COPD and bronchiectasis: aetiology and treatment Year: 2009